Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

Inclusion Criteria: * Confirmed diagnosis of multiple myeloma (either secretory or nonsecretory disease) * Relapsed or refractory disease * ECOG performance status 0-2 * Adequate hepatic/renal function and platelet count * If previously treated with an anthracycline, anthracenedione, or trastuzumab, must have left ventricular ejection fraction \> 50% * Fully recovered from any previous cancer treatments and/or major surgery Exclusion Criteria: * Prior allogeneic bone marrow transplant, including syngeneic transplant * Bone marrow transplant within 12 weeks prior to study * Known intracranial disease or epidural disease * Inability to tolerate Velcade * Inability to tolerate Decadron * Prior malignancy (within the last 3 years) * Clinically significant cardiovascular disease or condition * Active or chronically recurrent bleeding (eg, active peptic ulcer disease * Prolongation of PT or aPTT \> the ULN or fibrinogen \< the LLN * Clinically relevant active infection * Serious co-morbid medical conditions, including cirrhosis and chronic obstructive or chronic restrictive pulmonary disease * Any other cancer therapy within 4 weeks prior to study, with nitrosourea within 6 weeks prior to study * Investigational therapy within 4 weeks prior to study * Anti-platelet therapy within 2 weeks prior to study, other than low dose aspirin prophylaxis therapy and low dose heparin administration for management of IV access devices * Radiation therapy within 4 weeks prior to study * Major surgery within 4 weeks prior to study * Active autoimmune disease requiring immunosuppressive therapy * Known positive serology for HIV